Diseases mediated by transglutaminase such as Huntington's Disease spinobulbar atrophy spinocerebellar ataxia and dentatorubralpallidoluysian atrophy as well as inflammatory diseases of the central nervous system including multiple sclerosis rheumatoid arthritis and insulin dependent diabetes mellitus can be treated by administering a transglutaminase inhibitor such as monodansyl cadaverine monoamines and diamines such as cystamine putrescine GABA (gamma-amino benzoic acid) N-benzyloxy carbonyl ...

Diseases mediated by transglutaminase such as Huntington's Disease spinobulbar atrophy spinocerebellar ataxia and dentatorubralpallidoluysian atrophy as well as inflammatory diseases of the central nervous system including multiple sclerosis rheumatoid arthritis and insulin dependent diabetes mellitus can be treated by administering a transglutaminase inhibitor such as monodansyl cadaverine monoamines and diamines such as cystamine putrescine GABA (gamma-amino benzoic acid) N-benzyloxy carbonyl ...

Diseases mediated by transglutaminase, such as Huntington's Disease, spinobulbar atrophy, spinocerebellar ataxia, and dentatorubralpallidoluysian atrophy, as well as inflammatory diseases of the central nervous system, including multiple sclerosis, rheumatoid arthritis, and insulin dependent diabetes mellitus, can be treated by administering a transglutaminase inhibitor such as monodansyl cadaverine, monoamines and diamines such as cystamine, putrescine, GABA (gamma-amino benzoic acid), N-benzyl...

PROBLEM TO BE SOLVED: To allow recovery of lowered functional of motor and sensory nerves in patients suffering from diabetic neuropathy by using beraprost in combination with a medicine for diabetes. SOLUTION: Treatment of the diabetic neuropathy especially one accompanied by lowering in nervous conduction speed is performed by using (A) beraprost in combination with (B) a medicine for diabetes. As the component B an insulin-containing preparation or a medicine for diabetes for oral use specifi...

A method is provided for treatment of Parkinson's disease or controlling movement of a Parkinsonian patient by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, (for example, tolbutamide), or quinine.

A method is provided for treatment of neuronal insult, such as caused by lack of oxygen, which neurons are prone to Parkinsonian degeneration by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, for example, tolbutamide.

Non-insulin dependent or type 2 diabetes mellitus in a patient is treated by administering to the patient a hypoglycemic agent that enhances plasma concentrations of amylin and a therapeutically effective amount of an amylin antagonist.Hypoglycemic agents which enhance plasma concentrations of amylin can be sulfonylureas such as glibenclamide and tolbutamide.Amylin antagonists can be amylin 8-37 and CGRP 8-37.Administration of the amylin antagonist in conjunction with the hypoglycemic agent also...

A method is provided for treatment of neuronal insult, such as caused by lack of oxygen, which neurons are prone to Parkinsonian degeneration by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, for example, tolbutamide.

Non-insulin dependent, or type 2, diabetes mellitus in a patient is treated by administering to the patient a hypoglycemic agent that enhances plasma concentrations of amylin and a therapeutically effective amount of an amylin antagonist. Hypoglycemic agents which enhance plasma concentrations of amylin can be sulfonylureas such as glibenclamide and tolbutamide. Amylin antagonists can be amylin 8-37 and CGRP 8-37. Administration of the amylin antagonist in conjunction with the hypoglycemic agent...

A method is provided for treatment of Parkinson's disease or controlling movement of a Parkinsonian patient by administering an ATP-sensitive potassium channel blocker, such as a sulfonyl urea, (for example, tolbutamide), or quinine.